Real World Effectiveness of Population-Based Roll Out of Human Papillomavirus Vaccination Against Rates of Genital Warts
Menée sur 124 000 jeunes filles et femmes incluses dans une cohorte incluant plus de 2 millions de participantes vivant en Suède entre 2006 et 2010 (âge : 10 à 44 ans), cette étude évalue, du point de vue de l'incidence des verrues génitales et en fonction de l'âge à la vaccination, l'efficacité d'un vaccin quadrivalent contre une infection par le papillomavirus humain
Dr Leval and colleagues present novel data on the real-world effectiveness of population-based roll-out of human papillomavirus (HPV) vaccination against rates of genital warts among more than 2 million female residents of Sweden aged 10 to 44 years (1). The ability of the Swedish public health system to link unique personal identification numbers of residents to multiple registries allows an exceptional opportunity to examine impact of quadrivalent HPV vaccination on a representative sample of the Swedish population, in contrast with data examining ecological trends, which are inherently difficult to interpret. Sweden’s considerable investment in record linkage systems allowing the ability to comprehensively capture country-level coverage data not only on individual’s vaccination status but also on clinical outcome and treatment data on genital warts is exemplary and a step ahead of most countries worldwide.
Journal of the National Cancer Institute , éditorial en libre accès, 2013